DelMar Pharmaceuticals (NASDAQ:DMPI) posted its quarterly earnings results on Wednesday. The company reported ($0.14) EPS for the quarter, beating the consensus estimate of ($0.15) by $0.01, Yahoo Finance reports.
DelMar Pharmaceuticals (DMPI) traded up $0.03 during trading on Thursday, reaching $1.36. The company’s stock had a trading volume of 169,800 shares, compared to its average volume of 806,386. The firm has a market cap of $28.73, a PE ratio of -1.97 and a beta of 1.22. DelMar Pharmaceuticals has a 12-month low of $0.78 and a 12-month high of $5.20.
Separately, HC Wainwright set a $12.00 price target on DelMar Pharmaceuticals and gave the company a “buy” rating in a report on Thursday, January 4th.
DelMar Pharmaceuticals Company Profile
DelMar Pharmaceuticals, Inc is a clinical-stage drug development company. The Company focuses on the treatment of cancer. The Company is engaged in conducting clinical trials in the United States with its product candidate, VAL-083, as a treatment for glioblastoma multiforme (GBM), a form of brain cancer.
Receive News & Ratings for DelMar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DelMar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.